API
< Back to situations

[ORGANIZATION]

semaglutide

Featured in 44 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [GB] [SE]

Expanding therapeutic uses and regulatory concerns for GLP-1

43 clusters · 183 sources · last updated

Latest: Semaglutide shows efficacy in treating obesity in children aged 6 to 11

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

342 clusters · 1316 sources · last updated

Latest: GLP-1 medications linked to diverse health outcomes and access challenges

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, neurodegenerative, heart, sleep apnea, and addiction healt

[ACTIVE] [HEALTH] [US] [DK] [BR]

Novo Nordisk raises 2026 outlook on Wegovy demand

117 clusters · 557 sources · last updated

Latest: Omada Health and Novo Nordisk present new obesity treatment data

Novo Nordisk is navigating market volatility and patent risks, specifically the potential for generic competition as U.S. patents for its primary active ingredients expire in 2032. While the company faces intense competi

[ACTIVE] [HEALTH] [US] [BR] [DE]

GLP-1 receptor agonist research and safety scrutiny

13 clusters · 72 sources · last updated

Latest: FDA requires GLP-1 medication warnings for rare eye condition

Research into GLP-1 receptor agonists (GLP-1 RAs) continues to expand, investigating benefits beyond glycemic control and weight loss. Potential advantages include cardiovascular protection, kidney support, reduction in

[QUIET] [HEALTH] [DK] [BR] [US]

Novo Nordisk CagriSema clinical trial results

3 clusters · 13 sources · last updated

Latest: Novo Nordisk reports weight loss data for Wegovy and CagriSema

Novo Nordisk has released findings from Phase 3 clinical trials regarding its experimental medication, CagriSema, which combines cagrilintide and semaglutide to treat diabetes and obesity. Initial results from the Phase

[QUIET] [HEALTH] [BR]

Brazil plans semaglutide integration into SUS

12 clusters · 172 sources · last updated

Latest: Anvisa regulates weight-loss medications and seizes irregular supplements

The Brazilian Ministry of Health is progressing with plans to incorporate semaglutide-based weight-loss medications into the Unified Health System (SUS). On September 24, 2026, the Ministry submitted a formal request to

Also covered in